Skip to main content
227 results:
41. Science  
Following a deep understanding of disease biology, SphingoTec has developed novel biomarkers addressing diagnostically underserved critical care conditions. SphingoTec identified major pathways…  
42. Resource Center  
Scientific Publications Browse our scientific publications to learn more about how our biomarkers can impact patient care. Learn more Downloads Discover our brochures, product cataloge and white…  
43. Imprint  
Impressum SphingoTec GmbH Neuendorfstr. 15A 16761 Hennigsdorf Telefon: 03302 205650 E-Mail: Vertreten durch: SphingoTec GmbH Geschäftsführer: Dr. Andreas…  
44. Privacy Notice  
Privacy Policy 1. An overview of data protection General information The following information will provide you with an easy to navigate overview of what will happen with your personal data when…  
45. Network  
In collaboration with international key opinion leader networks, SphingoTec develops fundamental solutions for fighting mortality in acute diseases.  
46. Biomarker Out-Licensing  
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.  
47. Newsletter  
48. About Us  
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and…  
49. Request a Quote  
Disclaimer & Privacy notice  The information provided in this quote request will be forwarded to the distributors responsible for your area. Products based on the Nexus IB10 technology…  
50. SphingoTec’s innovative biomarkers to enable personalized medicine in septic organ failure  
SphingoTec announces a series of presentations demonstrating the utility of its innovative biomarkers in sepsis, positively impacting diagnostic and treatment decisions for critically ill patients.  
Search results 41 until 50 of 227